Macquarie Group
IRMD icon

Macquarie Group’s iRadimed IRMD Stock Holding History

Macquarie Group’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,710
Closed -$42K – 1842
2018
Q4 		$42K Sell
1,710
-4,995
-74% -$134K ﹤0.01% 1625
2018
Q3 		$249K Sell
6,705
-9,299
-58% -$251K ﹤0.01% 1442
2018
Q2 		$332K Buy
16,004
+1,600
+11% +$28.3K ﹤0.01% 1495
2018
Q1 		$203K Buy
14,404
+6,200
+76% +$88.3K ﹤0.01% 1702
2017
Q4 		$124K Buy
8,204
+7,100
+643% +$90.2K ﹤0.01% 1858
2017
Q3 		$11K Buy
+1,104
New +$10.5K ﹤0.01% 2110

Other funds holding IRMD

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Macquarie Group's IRMD Position: Q1 2019 in Review

Macquarie Group sold out of iRadimed (IRMD) in Q1 2019, closing a stake of 1,710 shares — an estimated $42K sold.

Macquarie Group first reported a position in IRMD in Q3 2017 and held it in 6 quarters. The position peaked at $332K in Q2 2018. 64 funds tracked by Wall St. Rank hold IRMD as of Q1 2019.

  • Macquarie Group reported no remaining iRadimed position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 1,710 iRadimed shares in Q1 2019, an estimated $42K.
  • Macquarie Group first reported a position in iRadimed in Q3 2017 and held it in 6 quarters.
  • Macquarie Group's iRadimed position peaked at $332K in Q2 2018.
  • 64 funds tracked by Wall St. Rank held iRadimed as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.